Roche, a leader in health, focusing on the research sector and the combined strengths in pharmaceuticals and diagnostics company, has introduced the test cobas DPX for use in systems cobas 6800/8800, expanding the menu newer platforms Roche molecular diagnostic screening assays donor next generation.
The test cobas DPX is a PCR hepatitis A (HAV) in human plasma double real-time assay for parvovirus B19 (B19V) and. Using tests for nucleic acid amplification (NAT) for detecting these viral targets is important in ensuring the safety of blood and plasma products step.
"Roche is committed to providing screening tests and more efficient blood plasma and increased coverage to ensure greater safety for patients," said Paul Brown , head of Roche Molecular Diagnostics. "Enter cobas DPX systems cobas 6800/8800 is an important step toward that goal, complementing our current screening test current donors for the detection of HIV, HCV, HBV, VNW and VEH ".
Using cobas DPX, testing centers and blood plasma can quickly identify and eliminate contaminated with HAV units, while minimizing the burden of B19V fund plasma. Perform NAT with test cobas DPX allows testing centers to increase process efficiency donations while preserving high security standards for plasma products used in transfusions and other therapeutic treatments for patients.
The test cobas DPX and systems cobas 6800/8800 are commercially available in markets that recognize the CE mark and are not currently available in the United States.
Roche is the world market leader in control and NAT blood plasma, with an estimated value of about 800 million Swiss francs. The nucleic acid based test allows early detection of active antigen tests that conventional antibodies or viral infections. The nucleic acid assays based on real-time PCR Roche used since 1998 to control blood and plasma products. Currently, more than 250 test centers worldwide use Roche's automated systems for monitoring blood and plasma.
Human plasma products are widely used in the treatment of chronic and hereditary diseases and disorders such as hemophilia and primary immunodeficiency diseases. Plasma is also used to treat patients who have suffered severe burns or trauma, and during major surgery. To support the therapeutic use, the human plasma can be collected from blood donations or directly from donors, and subsequently split its components, such as immunoglobulin, albumin and coagulation factors.
The systems cobas 6800 and 8800 are fully automated solutions designed for screening blood donors, control of viral load testing, women's health and microbiological analysis. They are available in medium and high processing capacity. PCR-based technology --galardonada the Nobel Prize - systems are designed to provide greater automation and processing capacity with faster results and provide users with more analytical flexibility to increase the overall efficiency of flows i work.
The systems provide up to 96 results in less than 3.5 hours, and in one 8 hour shift enables total of 384 results with the cobas 6800 and 960 with the cobas 8800. Both systems allow mixed batches, so that laboratories can perform up to three different tests in the same cycle without prior classification of samples. The systems also provide up to eight hours (cobas 6800) or four hours (cobas 8800) "time without manual operations" for which the interaction with the user required is minimal.